Theravance SVP granted 18,750 company shares

Miller Aine reported acquisition or exercise transactions in this Form 4 filing.

Accepted by SEC EDGAR 06/23/2026 - 05:49 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Miller Aine reported acquisition or exercise transactions in this Form 4 filing.

Theravance Biopharma, Inc. reported that senior vice president Aine Miller received a grant of 18,750 Ordinary Shares on June 19, 2026. The award was recorded at a price of $0.0000 per share, reflecting a compensation-related grant rather than a market purchase. Following this transaction, Miller directly holds 196,084 Ordinary Shares of Theravance Biopharma.

Insider Trade Summary

Grant/Award: 18,750 shares

Grant/Award 1 txn

Insider Miller Aine

Role SVP, DEV & HEAD OF IRE OFFICE

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	18,750	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 196,084 shares (Direct)

Holdings Before and After: Ordinary Shares, 177,334 to 196,084 shares (Direct)

Key Figures

Shares granted: 18,750 shares Post-transaction holdings: 196,084 shares Reported grant price: $0.0000 per share +1 more

4 metrics

Shares granted 18,750 shares Equity award to SVP Aine Miller on June 19, 2026

Post-transaction holdings 196,084 shares Ordinary Shares directly held by Aine Miller after grant

Reported grant price $0.0000 per share Accounting price for the 18,750-share equity award

Transaction date June 19, 2026 Date of grant/award acquisition

Key Terms

Ordinary Shares, grant/award acquisition, non-derivative

3 terms

Ordinary Shares financial

"The award covered 18,750 Ordinary Shares of Theravance Biopharma."

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

grant/award acquisition financial

"The Form 4 classifies the transaction as a grant/award acquisition."

non-derivative financial

"This is a non-derivative transaction involving Ordinary Shares."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Theravance Biopharma (TBPH) report for Aine Miller?

Theravance Biopharma reported that SVP Aine Miller received a grant of 18,750 Ordinary Shares. The transaction was coded as a grant/award acquisition and is classified as a non-derivative equity award, not an open-market share purchase or sale.

How many Theravance Biopharma (TBPH) shares does Aine Miller hold after this Form 4?

After the reported grant, Aine Miller directly holds 196,084 Ordinary Shares of Theravance Biopharma. This figure reflects her post-transaction position in non-derivative stock as disclosed in the Form 4 filing for June 19, 2026.

Was cash paid for the 18,750 Theravance Biopharma (TBPH) shares granted to Aine Miller?

No cash changed hands for this award, as the 18,750 Ordinary Shares were recorded at a transaction price of $0.0000 per share. This indicates a compensation-related equity grant rather than a purchase in the open market.

What does the transaction code "A" mean in the Theravance Biopharma (TBPH) Form 4?

The transaction code “A” in this Form 4 indicates a grant, award, or other acquisition of shares. For Aine Miller, it reflects a non-derivative equity award of 18,750 Ordinary Shares as part of her compensation, not a discretionary market trade.

Is the Aine Miller transaction in Theravance Biopharma (TBPH) a buy or a grant?

The transaction is a grant, not a buy. It is classified as a grant/award acquisition of 18,750 Ordinary Shares at a reported price of $0.0000 per share, consistent with stock-based compensation rather than an open-market purchase.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Miller Aine

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, DEV & HEAD OF IRE OFFICE

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	06/19/2026		A		18,750	A	$0	196,084	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Corinna Liebowitz, Attorney-in-Fact	06/23/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)